Boehringer Ingelheim Pharmaceuticals Inc. is aggressively moving to protect its franchises on three profitable diabetes drugs.
Aurobindo Pharma Ltd.'s bid to make generic copies of the drugs—Jardiance (empagliflozin), Glyxambi (empagliflozin/linagliptin), and Synjardi (empagliflozin/metformin)—would infringe three patents covering the products, its complaint filed in federal court in Delaware said.
It’s easy to see why Boehringer is eager to protect its franchise of empagliflozin products: in 2017, its flagship empagliflozin product Jardiance generated more than $1 billion in sales, the company said.
The patents at issue are U.S. Patent Nos. 8,551,957, 7,713,938 and/or 9,949,998. The last of those patents ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.